Testing PLM-102 for Hard-to-Treat Blood Cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called PLM-102 in adults whose acute myeloid leukemia (a serious blood cancer) has come back or stopped responding to standard treatment. The goal is to see if PLM-102 can help patients whose cancer has proven difficult to control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia or a related blood disorder that has relapsed (come back) or is refractory (not responding to treatment)
- You are generally able to care for yourself with minimal help (ECOG performance status 0–2)
- You have adequate liver and kidney function to safely receive the study drug
- You are at least 18 years old and can understand and sign an informed consent form
- If you can become pregnant, you agree to use effective birth control during the trial and for 90 days after treatment ends
- You have recovered from any prior cancer treatments and are ready to start a new therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.